- Home
- IBCP vs DVAX Comparison
IBCP vs DVAX Comparison
Compare IBCP & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBCP | DVAX |
|---|---|---|
| Founded | 1864 | 1996 |
| Country | United States | United States |
| Employees | N/A | 405 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.6M | 1.3B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | IBCP | DVAX |
|---|---|---|
| Price | $34.85 | $10.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $36.00 | $26.50 |
| AVG Volume (30 Days) | 155.2K | ★ 1.5M |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | ★ 10.56 | N/A |
| EPS | ★ 3.25 | N/A |
| Revenue | $222,890,000.00 | ★ $330,514,000.00 |
| Revenue This Year | N/A | $24.63 |
| Revenue Next Year | $5.16 | $15.85 |
| P/E Ratio | $10.78 | ★ N/A |
| Revenue Growth | 7.05 | ★ 26.73 |
| 52 Week Low | $26.75 | $9.20 |
| 52 Week High | $38.10 | $14.63 |
Technical Indicators
Market Signals| Indicator | IBCP | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 67.18 | 48.06 |
| Support Level | $33.23 | $10.76 |
| Resistance Level | $35.21 | $10.97 |
| Average True Range (ATR) | 0.81 | 0.26 |
| MACD | 0.15 | -0.05 |
| Stochastic Oscillator | 75.90 | 21.51 |
Price Performance
Historical ComparisonAbout IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.